Company profile: OcellO
1.1 - Company Overview
Company description
- Provider of CRO services for the drug discovery industry, developing clinically relevant in vitro human micro-tissue models for screening and profiling of small molecules and biologics to improve the efficiency of lead development.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OcellO
CITrials
HQ: United States
Website
- Description: Provider of pharmaceutical medical research conducting clinical trials across Phase I-IV to evaluate safety, efficacy, dosing, and long-term effectiveness of investigational and approved drugs. Offers studies in mental health conditions, including depression, anxiety, bipolar disorder, and schizophrenia, and women's health, including reproductive health and other gender-specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CITrials company profile →
Enavate Sciences
HQ: United States
Website
- Description: Provider of capital and strategic growth support to therapeutic and enabling technology companies, partnering with life sciences companies and their investors to advance and accelerate the development of novel therapies and help companies realize their potential.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enavate Sciences company profile →
Padagis
HQ: United States
Website
- Description: Provider of generic Rx and OTC pharmaceuticals, including Brinzolamide Ophthalmic Suspension for ocular hypertension/open-angle glaucoma, Naloxone HCl Nasal Spray for opioid overdose, and extended topical prescription creams, ointments, suspensions, gels, foams, sprays, patches, nasal, and suppositories. Offers Paragraph IV specialty products and U.S. and Israel manufacturing and distribution across multiple dosage forms, including controlled substances.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Padagis company profile →
IPA
HQ: Canada
Website
- Description: Provider of bioplatform-based, AI-driven antibody discovery and development services leveraging systems biology and multi-omics modeling. Offerings include target analysis and immunization, antibody discovery and characterization (sequencing and custom assays), developability profiling, and optimization/engineering (humanization, affinity maturation, chimerization). Includes LENSai Integrated Intelligence Technology for drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IPA company profile →
Network Partners
HQ: United States
Website
- Description: Provider of professional services and life sciences professionals to medical device, pharmaceutical, and biopharmaceutical industries, with core competencies in Regulatory Affairs, Medical Writing, Packaging Engineering, Labeling, Quality, and Project Management to help clients complete the work necessary to deliver products to patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Network Partners company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OcellO
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OcellO
2.2 - Growth funds investing in similar companies to OcellO
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OcellO
4.2 - Public trading comparable groups for OcellO
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →